Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.8/10
Best for: compounded semaglutide at one price per dose, with named pharmacies and coaching included
NexLife falls below our bar on oversight: the FDA has issued it a warning letter. It charges from $129 a month; its compounded tirzepatide, at $169, is 37% below the $269 median among the sellers we compare.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
microdose tier; standard plans start at $139/mo
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
Prices checked October 2026
NexLife is a LegitScript-certified telehealth platform selling compounded semaglutide at $139 a month and tirzepatide at $169, the same at every dose, with no membership. Longer plans cut the rate to $119 and $139 on 12 months. It also sells microdose and under-the-tongue tablet versions of both. NexLife Medical Group prescribes, and Absolute Pharmacy, Premium Compounding and Boudreaux's New Drug Store fill.
NexLife is a real, operating US company, and the FDA has issued it a warning letter. The letter is summarized at the top of this review. Read what it alleges before you decide, and raise it with the clinician who would prescribe for you. We rate NexLife 7.8/10 overall.
We know of no promo or coupon code for NexLife. Its listed price is $129 a month. Coupon sites advertising "NexLife discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how NexLife compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Six columns, each one computed from something NexLife has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
$169/month is 37% below the $269 median for compounded tirzepatide across the sellers we compare. A cheaper microdose price is also listed; Value is scored on the standard dose.
Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
A price is shown before the questionnaire starts. A live video visit is required, which is slower but the more careful intake.
The FDA has issued it a warning letter. It names the pharmacy that fills its prescriptions. It shows a price before asking for health information.
No state list is available to check, so this is held at the midpoint rather than scored on reach.
The price covers the medication, clinician visits, shipping and coaching.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
Taken from the terms NexLife publishes. Terms change, so check the current policy before you subscribe.
NexLife lists compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices re-verified
3-month plan $132 a month, 6-month $125, 12-month $119. Longer plans bill as chosen at checkout.
3-month plan $159 a month, 6-month $149, 12-month $139. Longer plans bill as chosen at checkout.
3-month $119 a month, 6-month $114, 12-month $109.
3-month $149 a month, 6-month $139, 12-month $129.
3-month $185 a month, 6-month $177, 12-month $165.
3-month $219 a month, 6-month $205, 12-month $199.
Check the price yourself before you pay
Every figure here comes from NexLife's own website, as of the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
NexLife names each pharmacy below as one that compounds or fills its prescriptions, in its own site, terms or filings. The quote under each one is the seller’s own wording.
“Pharmacy fulfillment. Prescriptions are fulfilled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), and Boudreaux’s New Drug Store (Lake Charles, LA), each state-licensed and operating under state board oversight and applicable sterile compounding standards.”
“Pharmacy fulfillment. Prescriptions are fulfilled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), and Boudreaux’s New Drug Store (Lake Charles, LA), each state-licensed and operating under state board oversight and applicable sterile compounding standards.”
“Pharmacy fulfillment. Prescriptions are fulfilled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), and Boudreaux’s New Drug Store (Lake Charles, LA), each state-licensed and operating under state board oversight and applicable sterile compounding standards.”
NexLife charges $129/month for its microdose tier; its standard plans start at $139/month and hold that rate across every dose.
For compounded tirzepatide, the median across the sellers we compare is $269/month, so NexLife's $169 is genuinely below the middle, not just advertised that way. Before you pay, compare NexLife's cancellation terms with other sellers' cancellation and refund policies.
bmiMD, at about $129/month, is the closest like-for-like alternative we review.
NexLife prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality. The molecule can be the one in Ozempic and Wegovy; what differs is the formulation, the concentration and the dose ladder. NexLife also lists a microdose plan, and the published evidence on GLP-1 microdosing is letters and commentary rather than trials.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at NexLife at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a proven equal to the shot. No human absorption study of sublingual semaglutide drops has been published.
NexLife tells you its price before you start the medical questionnaire, the pharmacy that fills its prescriptions, and that its pharmacy is accredited. It also offers coaching as part of the plan. The FDA has issued NexLife a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the named pharmacy is the detail that matters most: its license is the one you can look up. Across the market, the FDA's GLP-1 warning letters are mostly about what sellers said rather than what pharmacies made. How we weigh oversight, disclosure and price is set out in our scoring methodology.
NexLife competes on price, and at $169/month for compounded tirzepatide it competes well. The FDA warning letter is what to weigh against that, not a footnote to it. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
NexLife falls below our bar on oversight: the FDA has issued it a warning letter. It charges from $129 a month; its compounded tirzepatide, at $169, is 37% below the $269 median among the sellers we compare.
Starting at $129 a month. Check today's price, then start the intake.
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these two counts, another seller does better.
If none of these fits, our guide to alternatives to NexLife sets more sellers in the same category beside NexLife on price, states and what the price includes.
The words sellers use, defined. Tap any term.
Regulatory notice
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Cited across this NexLife review: primary regulatory filings, and peer-reviewed studies.
Plans start at $129 a month. Whether you qualify is a clinician's decision, made after your intake.